Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

Name: Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Published: 2022
License: Public Domain

Coherus Oncology, Inc. · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

cancer efficacy hepatocellular-carcinoma immunotherapy liver-cancer safety

hepatocellular carcinoma, phase 2, srf388, il-27, safety, efficacy, immunotherapy, cancer, immuno-oncology, liver cancer, atezolizumab, tecentriq

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 800894
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.